scorecardresearch

Strides Pharma to manufacture Pfizer’s Covid-19 drug

The drug consists of Nirmatrelvir tablets, which are co-packaged and co-administered with Ritonavir tablets.

pfizer-vaccine
The product has been authorised as a Covid-19 oral therapy for emergency use in the US and many other countries, amongst high-risk adults and high-risk paediatric patients.

Strides Pharma Science on Monday announced a sub-licensing agreement with the Medicines Patent Pool (MPP) to commercialise a generic version of Pfizer’s Covid-19 oral treatment in 95 low and middle-income markets. Pfizer’s Covid-19 oral treatment has received the US Food and Drug Administration’s (USFDA) emergency use authorisation for Covid-19 oral antiviral treatment.

Branded as Kovidax, the generic version of Pfizer’s oral drug will be launched in markets as part of Strides’ sub-licensing agreement with MPP. The product will be made at the company’s facility in Bengaluru. Strides said it had already secured its active pharmaceutical ingredients supplies through a preferred partnership arrangement.

The drug consists of Nirmatrelvir tablets, which are co-packaged and co-administered with Ritonavir tablets. The product has been authorised as a Covid-19 oral therapy for emergency use in the US and many other countries, amongst high-risk adults and high-risk paediatric patients.

Pfizer’s Covid-19 oral treatment has reduced the risk of hospitalisation or death by 89% within three days of symptom onset compared to a placebo.

It is administered as a dose of 300 mg of Nirmatrelvir with 100 mg tablet of Ritonavir, given twice daily for five days.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Most Read In Lifestyle